☆ 4.5 Editorial Material

Monoclonal antibodies for the prevention of Plasmodium falciparum malaria: a multi-target approach?

INFECTIOUS DISEASES (2023)

Related references

Note: Only part of the references are listed.

Article Infectious Diseases

RTS,S/AS01 malaria vaccine-proven safe and effective?

Anders Bjorkman et al.

Summary: In October 2021, WHO recommended the RTS,S malaria vaccine for children from age 5 months in regions with moderate to high malaria transmission. However, there are concerns about the mortality data from the malaria vaccine implementation programme (MVIP), including potential bias, inappropriate use of surrogate markers, statistically nonsignificant effect, and shortened assessment period. The claimed impact of the MVIP on mortality lacks scientific evidence, and the possibility of increased mortality among vaccinated girls compared to boys cannot be ruled out. The MVIP should follow planned analyses and provide data for independent assessment. Rigorous evaluation, especially regarding safety, is necessary for vaccine roll-out elsewhere.

LANCET INFECTIOUS DISEASES (2023)

Add to Collection

Article Microbiology

The dual action of human antibodies specific to Plasmodium falciparum PfRH5 and PfCyRPA: Blocking invasion and inactivating extracellular merozoites

Greta E. Weiss et al.

PLoS Pathogens (2023)

Add to Collection

Review Biotechnology & Applied Microbiology

Monoclonal antibodies for malaria prevention

Maya Aleshnick et al.

Summary: Monoclonal antibodies are specific proteins that can be used as prophylactics or therapeutics for infectious diseases. Although the high cost of production is a limitation, preliminary research shows that monoclonal antibodies have potential in preventing malaria.

MOLECULAR THERAPY (2022)

Add to Collection

Article Infectious Diseases

Safety, tolerability, and Plasmodium falciparum transmissionreducing activity of monoclonal antibody TB31F: a singlecentre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults

Saskia C. van der Boor et al.

Summary: TB31F is a well tolerated and highly potent monoclonal antibody capable of completely blocking transmission of P falciparum parasites from humans to mosquitoes.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Review Infectious Diseases

Monoclonal antibody therapies against SARS-CoV-2

Daniele Focosi et al.

Summary: This paper reviews the use of monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 in the ongoing COVID-19 pandemic and discusses their therapeutic effects, structural classification, immune escape, and limitations. It also explores the impact of the Omicron variant on treatment strategies and potential future developments for improved outcomes.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Medicine, General & Internal

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

R. L. Wu et al.

Summary: This study evaluated the safety and pharmacokinetics of L9LS, a next-generation antimalarial monoclonal antibody, and demonstrated its protective efficacy against controlled human malaria infection. L9LS was found to provide protection without evident safety concerns.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Article Infectious Diseases

Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years' follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial

Mehreen S. Datoo et al.

Summary: The R21/Matrix-M malaria vaccine maintains high efficacy and induces antibody concentrations that correlate with vaccine efficacy in African children.

LANCET INFECTIOUS DISEASES (2022)

Add to Collection

Article Infectious Diseases

Sources of persistent malaria transmission in a setting with effective malaria control in eastern Uganda: a longitudinal, observational cohort study

Chiara Andolina et al.

Summary: This study aimed to quantify the contribution of symptomatic and asymptomatic infections to P falciparum transmission in Tororo, Uganda. The findings suggest that individuals with asymptomatic infections are important drivers of malaria transmission, with school-aged children contributing to more than half of all mosquito infections. Demographically targeted interventions aimed at school-aged children could further reduce transmission in areas under effective vector control.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

A Monoclonal Antibody for Malaria Prevention

M. R. Gaudinski et al.

Summary: This study evaluated the safety, pharmacokinetics, and efficacy of a new long-acting monoclonal antibody CIS43LS against malaria. Results showed that administration of CIS43LS effectively prevented malaria after controlled infection, and there was a dose-dependent relationship between serum concentrations of CIS43LS and protective efficacy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Immunology

A Potent Anti-Malarial Human Monoclonal Antibody Targets Circumsporozoite Protein Minor Repeats and Neutralizes Sporozoites in the Liver

Lawrence T. Wang et al.

IMMUNITY (2020)

Add to Collection

Article Biochemistry & Molecular Biology

Human Antibodies that Slow Erythrocyte Invasion Potentiate Malaria-Neutralizing Antibodies

Daniel G. W. Alanine et al.

CELL (2019)

Add to Collection

Article Immunology

Pfs230 and Pfs48/45 Fusion Proteins Elicit Strong Transmission-Blocking Antibody Responses Against Plasmodium falciparum

Susheel K. Singh et al.

FRONTIERS IN IMMUNOLOGY (2019)

Add to Collection

Review Immunology

Antibodies against Plasmodium falciparum malaria at the molecular level

Jean-Philippe Julien et al.

NATURE REVIEWS IMMUNOLOGY (2019)

Add to Collection

Article Multidisciplinary Sciences

Unravelling the immune signature of Plasmodium falciparum transmission-reducing immunity

Will J. R. Stone et al.

NATURE COMMUNICATIONS (2018)

Add to Collection

Review Parasitology

Naturally acquired immunity to sexual stage P. falciparum parasites

Will J. R. Stone et al.

PARASITOLOGY (2016)

Add to Collection

Article Medicine, General & Internal

Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

H. Tinto et al.

LANCET (2015)

Add to Collection

© Peeref 2019-2024. All rights reserved.